|Articles|October 28, 2008

IMS Special Report

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Trending on PharmExec

IMS Special Report

Related Content

FDA Grants Emergency Use Authorization for Seegene’s Multiplex PCR Assay

Why High-Risk Patients Still Need Antivirals: Q&A with Gurinder S. Sidhu, M.D.

Developing Better Drugs, Not Just More Drugs: Q&A with David Hung

A Patent Strategy Pharma Execs May Be Overlooking: Means-Plus-Function Claims

What Policy Tools Move the Needle on API Manufacturing Capacity?

Trending on PharmExec

How Exposed is The U.S. Pharmaceutical Supply Chain to China’s Updated Export Control Regulations?

Pharmaceutical Executive Daily: Bristol Myers Squibb Expands Partnership with Nvidia

Why High-Risk Patients Still Need Antivirals: Q&A with Gurinder S. Sidhu, M.D.

Bristol Myers Squibb Expands Collaboration with Nvidia to Build AI Factory

A Patent Strategy Pharma Execs May Be Overlooking: Means-Plus-Function Claims